# Scribe Therapeutics Inc. (SCTX)

> Source: Nexqual · https://nexqual.com/SCTX · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Scribe Therapeutics Inc. (SCTX), nexqual.com/SCTX" · informational, not investment advice.

**Price:** USD 17.44 (-0.57% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 17.54 · day 16.98–18.27 · 52w 13.5–39.6 · market cap $330M · NGM

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (4 analysts), mean target USD 57 (range 50–60).
- Total return with dividends: 1Y -7.5% vs S&P 500 +14.8%; 5Y -10.5% vs S&P 500 +79.1%.
- Next earnings: 2026-11-11 (date not yet confirmed by the company), EPS estimate USD -1.03, revenue estimate $3.7M. All companies reporting that day: https://nexqual.com/earnings/2026-11-11
- Dividend: SCTX paid no cash dividend in the last five years.
- Short interest: 1,118,447 shares (as of 2026-10-15), 2.0 days to cover.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
Earnings yield -11.19%

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 4 analysts; mean target USD 57 (low 50, high 60).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-03 | HC Wainwright & Co. | Reiterated | Buy | $60 |
| 2026-08-31 | HC Wainwright & Co. | Initiated | Buy | $60 |
| 2026-08-18 | Wells Fargo | Initiated | Overweight | $60 |
| 2026-08-18 | Leerink Partners | Initiated | Outperform | $37 |
| 2026-08-18 | Guggenheim | Initiated | Buy | $50 |

## Total return (dividends reinvested)
|  | 1Y (from 2026-07-27) | 5Y (from 2026-07-27) |
|---|---|---|
| Total return | -7.5% | -10.5% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | — | — |
| Volatility (annualized) | 132.1% | 181.1% |
| Max drawdown | -58.6% (Aug 2026→Oct 2026) | -54.9% (Aug 2026→Oct 2026) |

## Dividends
SCTX paid no cash dividend in the last five years.

## Short interest
1,118,447 shares sold short, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 790,538 shares (+41.5%). Days to cover: 2.0 (short shares ÷ average daily volume).

## Peers (Biotechnology)
ORKA (Oruka Therapeutics, Inc.) USD 96.65 +0.71% · LGND (Ligand Pharmaceuticals Incorpor) USD 317.33 -0.45% · IOVA (Iovance Biotherapeutics, Inc.) USD 9.56 -35.45% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.39 -1.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.45 -0.04% · ABVX (Abivax SA) USD 89.06 -0.87%

## More
Full page: https://nexqual.com/SCTX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-1.03 | $0.00 | −$1.03 | $3.7M | 3 |
| Next quarter (ends 2026-12-31) | $-1.06 | $0.00 | −$1.06 | $3.7M | 3 |
| Current fiscal year (ends 2026-12-31) | $-5.59 | $0.00 | −$5.59 | $11.6M | 2 |
| Next fiscal year (ends 2027-12-31) | $-3.62 | $0.00 | −$3.62 | $6.7M | 3 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$2.62 | −$3.72 | Beat +29.6% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).